{"id":"radotinib-hcl","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Neutropenia"},{"rate":"15-25%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting the BCR-ABL tyrosine kinase, radotinib HCl prevents the uncontrolled growth of leukemic cells, leading to a reduction in disease progression and improvement in patient outcomes.","oneSentence":"Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:14.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) in chronic phase and accelerated phase"}]},"trialDetails":[{"nctId":"NCT06461078","phase":"PHASE1","title":"Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-07-22","conditions":"Drug Kinetics","enrollment":24},{"nctId":"NCT06665412","phase":"","title":"Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-24","conditions":"Chronic Phase Ph+ Chronic Myeloid Leukemia","enrollment":168},{"nctId":"NCT03459534","phase":"PHASE3","title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2018-06-25","conditions":"Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory","enrollment":173},{"nctId":"NCT04691661","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2021-09-09","conditions":"Parkinson Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SUPECT"],"phase":"phase_3","status":"active","brandName":"Radotinib HCl","genericName":"Radotinib HCl","companyName":"Il-Yang Pharm. Co., Ltd.","companyId":"il-yang-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML). Used for Chronic myeloid leukemia (CML) in chronic phase and accelerated phase.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}